Understanding SARS-CoV-2-induced systemic amyloidosis

In a recent analysis, researchers investigated the formation of amyloid fibrils in coronavirus disease 2019 (COVID-19) patients and posted their results to the bioRxiv* preprint server.

The world is witnessing a massive surge in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cases with over 270 million reported cases to date. Several coronaviruses (OC43, 229E, NL63, HKU1) are known to infect humans causing respiratory disorders; however, COVID-19 has been found to affect multiple organ systems causing extra-respiratory tract complications such as heart failure, peripheral neuropathy, central nervous system (CNS) disorders, and blood coagulation.

Study: Amyloidogenesis of SARS-CoV-2 Spike Protein. Image Credit: Dotted Yeti/ShutterstockStudy: Amyloidogenesis of SARS-CoV-2 Spike Protein. Image Credit: Dotted Yeti/Shutterstock

The study

In the present study, researchers investigated if the SARS-CoV-2 S protein could cause amyloidosis. Coronaviruses use their surface spike (S) protein to attach with host cells. About 316 spike peptides (15-mers with 11 amino acid [aa] overlap) were screened initially in two equal sub-pools and assayed in vitro for amyloid fibril formation.

Further, they generated 20 aa peptide sequences to find the most amyloidogenic sequences by using the WALTZ prediction algorithm. The peptides were lyophilized and dissolved in hexafluoroisopropanol (HFIP), followed by dilution in PBS buffer. They were maintained at a concentration of 0.1 mg/ml (10% HFIP) and observed for the formation of amyloid fibrils in vitro. The formation kinetics was monitored using Thioflavin T (ThT), Congo red birefringence (CR), and negative stain transmission electron microscopy (TEM).


The team discovered seven synthetic (amyloidogenic) peptides which were 20 amino acids in length within the S protein and found that six of them were in beta-sheet conformation as observed in the cryo-EM structure of SARS-CoV-2 S protein in its closed state. It was noted that these peptides in isolation could aggregate as fibrils at 37°C during incubation. Of these seven peptides, three peptides were found to meet the criteria of amyloid fibrils: sigmoid ThT kinetics, congophilicity, and ultrastructural fibrillar morphology. These peptides were Spike191, Spike532, and Spike1165, which are named according to the starting position of the S-protein.

Further, the researchers analyzed the fibril formation with these seven peptides as a mixture resulting in sigmoidal ThT kinetics based on a nucleation-dependent mechanism and noticed that the fibril morphology was similar to that of Spike191 indicating that this peptide was dominant in the mixture.

It is known that proteolysis of precursor proteins initiates amyloid formation in several diseases like Alzheimer’s disease, British and Danish dementia, and Finnish amyloidosis. The S protein of SARS-CoV-2 is also reported to be proteolyzed in hosts as an immune response and therefore, to understand the plausible mechanism of fibril formation, the full-length S protein was cleaved in vitro by using the enzyme, neutrophil elastase (NE). NE, secreted by neutrophils, was selected after positive results of in silico proteolysis of S protein were obtained. The analysis revealed that full-length S protein can not form fibrils and neither could NE alone; however, co-incubation of the two proteins formed fibrils indicative of proteolytic cleavage by NE that resulted in a Spike191-like peptide.


The findings reported in the study provide an understanding of amyloidosis observed in COVID-19 patients. COVID-19 induces multifactorial and complex pathogenesis like acute respiratory distress syndrome (ARDS) from several inflammatory reactions of the innate immune system. Cytokine storm, cardiac, neural, and renal damage have also been reported due to COVID-19.

Several studies observed blood coagulation in COVID-19 patients due to aggregation of extracellular amyloid fibrils.

Furthermore, it has been reported that NE is overexpressed at sites of inflammation and vaccine administration. Globally, over eight billion COVID-19 vaccine doses have been administered so far and a majority of them are mRNA-based vaccines that deliver information to encode the SARS-CoV-2 S protein as the main antigen.  Recently, the formation of fibrils was noted in a human at the site of mRNA-vaccine injection and in lymph nodes within 24 hours of administration.

The findings observed that endoproteolysis of S protein by NE, which generates peptides such as 193-202 segment, and possibly other amyloidogenic segments by other proteases could form amyloid fibrils. Complications like fibrinolysis, blood clotting, cerebral amyloid angiopathy, FXII Kallikrein/Kinin activation, and thromboinflammation have been linked with amyloidosis which could suggest a possible link between COVID-19 phenotypes and amyloidogenesis of S-protein.

In conclusion, the authors proposed that inflammation combined with aggregates of amyloidogenic peptides of SARS-CoV-2 S proteins might induce systemic amyloidosis.

*Important notice

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Tarun Sai Lomte

Written by

Tarun Sai Lomte

Tarun is a writer based in Hyderabad, India. He has a Master’s degree in Biotechnology from the University of Hyderabad and is enthusiastic about scientific research. He enjoys reading research papers and literature reviews and is passionate about writing.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sai Lomte, Tarun. (2021, December 21). Understanding SARS-CoV-2-induced systemic amyloidosis. News-Medical. Retrieved on November 30, 2022 from https://www.news-medical.net/news/20211221/Understanding-SARS-CoV-2-induced-systemic-amyloidosis.aspx.

  • MLA

    Sai Lomte, Tarun. "Understanding SARS-CoV-2-induced systemic amyloidosis". News-Medical. 30 November 2022. <https://www.news-medical.net/news/20211221/Understanding-SARS-CoV-2-induced-systemic-amyloidosis.aspx>.

  • Chicago

    Sai Lomte, Tarun. "Understanding SARS-CoV-2-induced systemic amyloidosis". News-Medical. https://www.news-medical.net/news/20211221/Understanding-SARS-CoV-2-induced-systemic-amyloidosis.aspx. (accessed November 30, 2022).

  • Harvard

    Sai Lomte, Tarun. 2021. Understanding SARS-CoV-2-induced systemic amyloidosis. News-Medical, viewed 30 November 2022, https://www.news-medical.net/news/20211221/Understanding-SARS-CoV-2-induced-systemic-amyloidosis.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Study suggests the behavior of an emergent SARS-CoV-2 variant may be sensitive to the immunologic and demographic context of its location